Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
Terminated
Romark Laboratories L.C.
Phase 3
2006-12-01
The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared
to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
Completed
Cubist Pharmaceuticals LLC
Phase 2
2007-06-26
This is a research study designed to look at the efficacy and safety of daptomycin given at a
dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections
caused by Staphylococci. These types of bacteria are among the most common types of bacteria
causing infections of prosthetic joints.
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
Terminated
Novartis Pharmaceuticals
Phase 3
2006-04-01
This study evaluated the efficacy and safety of daptomycin compared to vancomycin or
teicoplanin for the treatment of complicated skin and soft tissue infections
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
Terminated
Cubist Pharmaceuticals LLC
Phase 2
2008-09-17
The overall goals of this study are to compare the safety and efficacy of daptomycin
monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels
of 15 to 20 μg/mL for the treatment of methicillin-resistant S. aureus bacteremia (MRSA),
including right-sided infective endocarditis (RIE).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
